Last viewed:
BNTX
Prices are updated after-hours
BNTX
|
News
|
$88.53
0.59%
0.59%
360K
|
Health Technology
(0.0% 1d)
(-5.4% 1m)
(-24.7% 1y)
(0.0% 2d)
(0.0% 3d)
(2.1% 7d)
(Infinity%
volume)
Earnings Calendar:
Market Cap: $ 21,045,859,320
http://www.biontech.de
Sec
Filling
|
Patents
| 1310 employees
BioNTech SE operates as a clinical-stage biotechnology company. It operates through the following business units: Biotech Business and External Services. The Biotech Business unit consists of Clinical, Technology Platform and Manufacturing segments. It also includes business services operations. The External Services unit consists of External Services segment, which includes activities related to the sale of diagnostic products, peptides, retroviral vectors for clinical supply, development and manufacturing services. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
diagnostics
msa
dividends
add to watch list
Paper trade
email alert is off
Press-releases
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
Published: 2024-04-22
(Crawled : 11:00)
- globenewswire.com
BNTX
|
News
|
$88.53
0.59%
0.59%
360K
|
Health Technology
| 2.65%
| O: 1.33%
H: 2.12%
C: 1.3%
first
report
update
financial
results
Understanding the mRNA Therapeutics Market's -8.6% Decline: Insights from BCC Research
Published: 2024-04-10
(Crawled : 14:30)
- prnewswire.com
OMGA
|
$2.345
-1.88%
-1.92%
300K
|
| -20.86%
| O: -0.33%
H: 0.17%
C: 0.0%
CVAC
|
$2.585
2.17%
2.13%
610K
|
Health Technology
| -14.81%
| O: -0.67%
H: 1.36%
C: 0.0%
BNTX
|
News
|
$88.53
0.59%
0.59%
360K
|
Health Technology
| -2.27%
| O: -1.69%
H: 0.97%
C: 0.14%
mrna
research
therapeutics
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
Published: 2024-04-07
(Crawled : 20:20)
- globenewswire.com
BNTX
|
News
|
$88.53
0.59%
0.59%
360K
|
Health Technology
| -1.37%
| O: 1.38%
H: 0.2%
C: -1.27%
candidate
cancer
pancreatic
tumor
immunotherapy
for
response
show
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Published: 2024-03-27
(Crawled : 20:00)
- globenewswire.com
BNTX
|
News
|
$88.53
0.59%
0.59%
360K
|
Health Technology
| -5.34%
| O: -0.08%
H: 1.01%
C: -0.7%
MTNB
|
$0.1815
0.83%
-0.61%
770K
|
Health Technology
| -37.91%
| O: -3.38%
H: 2.32%
C: -3.25%
business
update
biopharma
financial
results
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
Published: 2024-03-20
(Crawled : 10:00)
- globenewswire.com
NVSEF
|
News
|
$95.11
6.88%
490
|
Health Technology
| -1.85%
| O: -1.37%
H: 0.0%
C: -1.58%
NVS
|
News
|
$97.28
2.27%
0.31%
3.7M
|
Health Technology
| -1.61%
| O: -0.62%
H: 0.45%
C: 0.34%
BNTX
|
News
|
$88.53
0.59%
0.59%
360K
|
Health Technology
| -6.49%
| O: -5.51%
H: 1.33%
C: 1.2%
management
commercial
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
Published: 2024-03-20
(Crawled : 11:00)
- biospace.com/
BNTX
|
News
|
$88.53
0.59%
0.59%
360K
|
Health Technology
| -6.49%
| O: -5.51%
H: 1.33%
C: 1.2%
AUTL
|
$4.5
-1.32%
-1.33%
1.7M
|
Health Technology
| -26.45%
| O: 1.45%
H: 5.33%
C: 4.13%
year
update
financial
results
Lipid-Nanoparticle Based Genomic Medicines Market worth $32.5 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
Published: 2024-03-18
(Crawled : 14:00)
- prnewswire.com
CVAC
|
$2.585
2.17%
2.13%
610K
|
Health Technology
| -23.33%
| O: 0.0%
H: 0.0%
C: -2.73%
BNTX
|
News
|
$88.53
0.59%
0.59%
360K
|
Health Technology
| -4.83%
| O: 0.48%
H: 1.18%
C: 0.08%
ABUS
|
$2.74
3.79%
3.65%
1.1M
|
Health Technology
| 0.76%
| O: 0.38%
H: 0.38%
C: -3.42%
report
genomic
market
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
Published: 2024-03-14
(Crawled : 11:00)
- globenewswire.com
BNTX
|
News
|
$88.53
0.59%
0.59%
360K
|
Health Technology
| -6.32%
| O: 0.11%
H: 0.3%
C: -1.21%
AUTL
|
$4.5
-1.32%
-1.33%
1.7M
|
Health Technology
| -16.79%
| O: 1.82%
H: 12.19%
C: 2.15%
business
year
therapeutics
financial
results
CTXTQ ALERT: Levi & Korsinsky, LLP Commences an Investigation of Cyxtera Technologies, Inc. (CYXTQ) f/k/a Starboard Value Acquisition (SVAC)
Published: 2024-03-12
(Crawled : 19:00)
- prnewswire.com
BNTX
|
News
|
$88.53
0.59%
0.59%
360K
|
Health Technology
| -8.06%
| O: 0.01%
H: 0.98%
C: -1.87%
acquisition
ALVR IMPORTANT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
Published: 2024-03-12
(Crawled : 19:00)
- prnewswire.com
BNTX
|
News
|
$88.53
0.59%
0.59%
360K
|
Health Technology
| -8.06%
| O: 0.01%
H: 0.98%
C: -1.87%
ALVR
|
$0.7952
4.22%
4.05%
280K
|
Health Technology
| 2.7%
| O: -0.14%
H: 1.49%
C: -1.43%
deadline
global
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount